€76.90
3.69% today
Madrid, Dec 30, 05:35 pm CET
ISIN
ES0169501022
Symbol
PHM
Sector
Industry

Pharma Mar Target price 2024 - Analyst rating & recommendation

Pharma Mar Classifications & Recommendation:

Buy
50%
Hold
33%
Sell
17%

Pharma Mar Price Target

Target Price €74.27
Price €76.90
Deviation
Number of Estimates 6
6 Analysts have issued a price target Pharma Mar 2025 . The average Pharma Mar target price is €74.27. This is lower than the current stock price. The highest price target is , the lowest is .
A rating was issued by 6 analysts: 3 Analysts recommend Pharma Mar to buy, 2 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Pharma Mar stock has an average upside potential 2025 of . Most analysts recommend the Pharma Mar stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million € 158.15 158.83
19.45% 0.43%
EBITDA Margin 0.26% 5.49%
98.94% 2,017.67%
Net Margin 0.67% 3.29%
97.27% 391.60%

6 Analysts have issued a sales forecast Pharma Mar 2024 . The average Pharma Mar sales estimate is

€159m
Unlock
. This is
4.89% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
€169m 1.42%
Unlock
, the lowest is
€140m 16.17%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 €158m 19.45%
2024
€159m 0.43%
Unlock
2025
€183m 15.41%
Unlock
2026
€249m 35.77%
Unlock
2027
€381m 53.13%
Unlock
2028
€540m 41.67%
Unlock

4 Analysts have issued an Pharma Mar EBITDA forecast 2024. The average Pharma Mar EBITDA estimate is

€8.7m
Unlock
. This is
1,928.77% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
€27.7m 6,340.70%
Unlock
, the lowest is
€-2.0m 565.12%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 €410k 99.15%
2024
€8.7m 2,027.73%
Unlock
2025
€80.3m 819.97%
Unlock
2026
€86.0m 7.16%
Unlock
2027
€158m 83.14%
Unlock

EBITDA Margin

2023 0.26% 98.94%
2024
5.49% 2,017.67%
Unlock
2025
43.78% 697.45%
Unlock
2026
34.55% 21.08%
Unlock
2027
41.33% 19.62%
Unlock

4 Pharma Mar Analysts have issued a net profit forecast 2024. The average Pharma Mar net profit estimate is

€5.2m
Unlock
. This is
639.80% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
€20.9m 2,862.02%
Unlock
, the lowest is
€-5.5m 875.23%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 €1.1m 97.80%
2024
€5.2m 393.20%
Unlock
2025
€58.7m 1,024.14%
Unlock
2026
€91.9m 56.61%
Unlock
2027
€130m 41.27%
Unlock

Net Margin

2023 0.67% 97.27%
2024
3.29% 391.60%
Unlock
2025
32.01% 872.95%
Unlock
2026
36.93% 15.37%
Unlock
2027
34.07% 7.74%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Dec '23 2024
Estimates
Earnings Per Share 0.06 0.30
97.80% 400.00%
P/E 269.61
EV/Sales 8.23

4 Analysts have issued a Pharma Mar forecast for earnings per share. The average Pharma Mar <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

€0.30
Unlock
. This is
650.00% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
€1.18 2,850.00%
Unlock
, the lowest is
€-0.31 875.00%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 €0.06 97.80%
2024
€0.30 400.00%
Unlock
2025
€3.33 1,010.00%
Unlock
2026
€5.21 56.46%
Unlock
2027
€7.36 41.27%
Unlock

P/E ratio

Current 2,262.04 3,977.22%
2024
269.61 88.08%
Unlock
2025
24.00 91.10%
Unlock
2026
15.33 36.13%
Unlock
2027
10.85 29.22%
Unlock

Based on analysts' sales estimates for 2024, the Pharma Mar stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 7.83 108.24%
2024
8.23 5.10%
Unlock
2025
7.13 13.35%
Unlock
2026
5.25 26.35%
Unlock
2027
3.43 34.69%
Unlock
2028
2.42 29.41%
Unlock

P/S ratio

Current 8.37 85.45%
2024
8.80 5.14%
Unlock
2025
7.63 13.35%
Unlock
2026
5.62 26.35%
Unlock
2027
3.67 34.69%
Unlock
2028
2.59 29.41%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today